The SirPAD trial marks a significant milestone in vascular intervention, positioning MagicTouch PTA as a promising future alternative for PAD treatment
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
DBT-BIRAC, BioE3 and the Rs 10,000-crore Biopharma SHAKTI scheme aim to accelerate innovation, biomanufacturing and exports
A joint position paper warns that Europe is the only major global region without a dedicated biomanufacturing initiative
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The center brings together hands on technology demonstrations, application expertise, and commercial operations
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Subscribe To Our Newsletter & Stay Updated
